The Pharma Letter1h
ABL Bio leaps as it announces deal with GSK
South Korean clinical-stage biotech ABL Bio (Kosdaq: 298380) on Sunday announced a worldwide licensing agreement enabling GSK ...
pharmaphorum1h
GSK makes fresh neuroscience foray with £2bn+ ABL deal
GSK's clinical-stage pipeline is currently focused on oncology, respiratory, immunology and inflammation, and infectious ...
Medical Dialogues8h
GlaxoSmithKline Pharma Upendra Singh resigns as Commercial Head - General Medicines
Mumbai: GlaxoSmithKline Pharmaceuticals Limited has announced the resignation of Upendra Singh, Commercial Head - General ...
KED Global9h
ABL Bio lands $2.8 billion license-out deal with GSK
ABL Bio Inc., a South Korean biotech company, will license out its proprietary blood-brain barrier shuttle platform, called ...
Le Lézard15h
ABL Bio Announces Grabody-B Brain Delivery Platform License Agreement with GSK to Develop Novel Medicines for Neurodegenerative Diseases
ABL Bio Inc. (KOSDAQ: 298380), a clinical-stage biotech company developing bispecific antibody technology for immuno-oncology and neurodegenerative diseases, announced a worldwide licensing agreement ...